SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. – CORT

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On December 8, 2021, Corcept disclosed in a filing with the U.S. Securities and Exchange Commission that "[o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorney's Office for the District of New Jersey (the 'NJ USAO') pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) seeking information relating to the sale and promotion of Korlym, Corcept's relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym." Corcept further disclosed that "[t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena." 

On this news, Corcept's stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:
Robert S. WilloughbyPomerantz LLP 
[email protected] 
888-476-6529 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-corcept-therapeutics-inc---cort-301470370.html

SOURCE Pomerantz LLP